Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Elpiscience Biopharma Ltd. currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 3 distinct examiners. The prosecution is occurring across 2 distinct art units, which shows some technical variety within the company's biotechnology filings.
The busiest examiner for this portfolio is LANDSMAN, ROBERT S, who is responsible for 1 pending office action. Since there are 3 pending office actions and 3 distinct examiners, each examiner is currently handling exactly one case. The 2 distinct art units indicate that the workload is split between different specialized sections of the patent office. This distribution across 3 distinct examiners provides multiple perspectives on the applications.
Practitioners should observe that the 3 distinct examiners mean that no single individual has a dominant influence over the portfolio. Because LANDSMAN, ROBERT S only manages 1 pending action, the risk is spread across the 3 distinct examiners. The 2 distinct art units suggest that the 3 pending office actions are grouped into different technical sub-categories. This spread defines the current prosecution landscape for Elpiscience Biopharma Ltd.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (33%) |
| §112 only | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANDSMAN, ROBERT S | 1 | 81.3% | +13.0% |
| HADDAD, MAHER M | 1 | 50.4% | +53.9% |
| BERHANE, SELAM | 1 | 58.4% | +56.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18292922 | NOVEL ANTI-SIRPA ANTIBODIES | LANDSMAN, ROBERT S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246516 | NOVEL ANTI-CLAUDIN18 ANTIBODIES | BERHANE, SELAM | 62d |
| 18292922 | NOVEL ANTI-SIRPA ANTIBODIES | LANDSMAN, ROBERT S | — |
| 18254606 | NOVEL CONJUGATE MOLECULES TARGETING CD39 AND TGFBETA | HADDAD, MAHER M | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18292922 | NOVEL ANTI-SIRPA ANTIBODIES | LANDSMAN, ROBERT S | — | §112 | Non-Final OA | — | Pending | Jan 28, 2024 |
| 18254606 | NOVEL CONJUGATE MOLECULES TARGETING CD39 AND TGFBETA | HADDAD, MAHER M | 1641 | §102 | Final Rejection | — | Pending | May 26, 2023 |
| 18246516 | NOVEL ANTI-CLAUDIN18 ANTIBODIES | BERHANE, SELAM | 1675 | §112 | Final Rejection | 62d | Pending | Mar 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial